Related Experiment Video
Updated: Jun 22, 2026
06:10
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Stable nonviral gene transfer into primary human T cells
T Magg1, S Hartrampf, M H Albert
1Department of Pediatric Hematology/Oncology, Dr. von Haunersches Kinderspital, Munich, Germany.
Human Gene Therapy
|June 3, 2009
Summary
This study demonstrates a nonviral method for stable genetic modification of human T cells. The technique achieves high purity and functionality, paving the way for gene therapy research and applications.
Area of Science:
- Immunology
- Molecular Biology
- Gene Therapy
Background:
- Genetic modification of T cells is crucial for research and therapeutic development.
- Current methods often suffer from low efficiency, toxicity, and specialized requirements.
Purpose of the Study:
- To investigate the Amaxa Nucleofector platform for nonviral transfection of primary human T cells.
- To achieve stable and homogeneous genetic modification of T cells for functional studies and therapeutic applications.
Main Methods:
- Utilized the Amaxa Nucleofector platform for nonviral T cell transfection.
- Employed a dual-promoter plasmid for co-expression of a gene of interest and a cell surface marker.
- Implemented immunomagnetic cell enrichment for purification of modified T cells.
Main Results:
- Achieved highly purified populations of gene-modified human T cells.
- Demonstrated stable and homogeneous transfection after repeated enrichment.
- Confirmed that modified T cells remained fully functional.
Conclusions:
- The Amaxa Nucleofector platform offers an effective nonviral technique for stable genetic modification of human T cells.
- This method enables homogeneous and functional gene expression in T cells.
- Facilitates future research in T cell physiology and the development of T cell-based gene therapies.
